- Home
- EBS vs TBPH Comparison
EBS vs TBPH Comparison
Compare EBS & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EBS
- TBPH
- Stock Information
- Founded
- EBS 1998
- TBPH 2013
- Country
- EBS United States
- TBPH United States
- Employees
- EBS N/A
- TBPH N/A
- Industry
- EBS Biotechnology: Pharmaceutical Preparations
- TBPH Biotechnology: Pharmaceutical Preparations
- Sector
- EBS Health Care
- TBPH Health Care
- Exchange
- EBS Nasdaq
- TBPH Nasdaq
- Market Cap
- EBS 459.6M
- TBPH 485.8M
- IPO Year
- EBS 2006
- TBPH N/A
- Fundamental
- Price
- EBS $8.09
- TBPH $9.59
- Analyst Decision
- EBS Strong Buy
- TBPH Buy
- Analyst Count
- EBS 2
- TBPH 4
- Target Price
- EBS $14.00
- TBPH $13.75
- AVG Volume (30 Days)
- EBS 999.1K
- TBPH 217.1K
- Earning Date
- EBS 11-06-2024
- TBPH 11-12-2024
- Dividend Yield
- EBS N/A
- TBPH N/A
- EPS Growth
- EBS N/A
- TBPH N/A
- EPS
- EBS N/A
- TBPH N/A
- Revenue
- EBS $1,125,500,000.00
- TBPH $63,192,000.00
- Revenue This Year
- EBS $6.64
- TBPH $11.41
- Revenue Next Year
- EBS $7.95
- TBPH $37.36
- P/E Ratio
- EBS N/A
- TBPH N/A
- Revenue Growth
- EBS 2.05
- TBPH 15.93
- 52 Week Low
- EBS $1.42
- TBPH $7.44
- 52 Week High
- EBS $15.10
- TBPH $11.71
- Technical
- Relative Strength Index (RSI)
- EBS 39.08
- TBPH 50.13
- Support Level
- EBS $8.35
- TBPH $9.62
- Resistance Level
- EBS $8.86
- TBPH $10.08
- Average True Range (ATR)
- EBS 0.50
- TBPH 0.31
- MACD
- EBS -0.11
- TBPH -0.06
- Stochastic Oscillator
- EBS 17.58
- TBPH 25.00
About EBS Emergent Biosolutions Inc.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company operates across three different segments, namely Commercial, Products, and Services. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.
About TBPH Theravance Biopharma Inc.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).